Peter Bradding

Leicester, ENG LE17RH, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 120 publications

Senicapoc in Patients with Idiopathic Pulmonary Fibrosis or Other Progressive Fibrotic Interstitial Lung Diseases: Protocol for a Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Trial.

Senicapoc in Patients with Idiopathic Pulmonary Fibrosis or Other Progressive Fibrotic Interstitial Lung Diseases: Protocol for a Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Trial.

Journal: Diagnostics (Basel, Switzerland)

Published: April 28, 2026

The Airway Transcriptome in Type 2 Cytokine Biomarker-High and -Low Severe Asthma.

The Airway Transcriptome in Type 2 Cytokine Biomarker-High and -Low Severe Asthma.

Journal: Allergy

Published: March 31, 2026

Validation of the English Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q).

Validation of the English Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q).

Journal: Allergy

Published: March 24, 2026

Symptom burden to characterise, predict, and prevent asthma attacks: a patient-level meta-analysis of randomised trials and translational prospective studies.

Symptom burden to characterise, predict, and prevent asthma attacks: a patient-level meta-analysis of randomised trials and translational prospective studies.

Journal: The Lancet. Respiratory medicine

Published: March 02, 2026

The KCa3.1 K+ Channel and Cardiovascular Disease: An Upstream Target Linking Inflammation, Fibrosis and Electrical Instability.

The KCa3.1 K+ Channel and Cardiovascular Disease: An Upstream Target Linking Inflammation, Fibrosis and Electrical Instability.

Journal: Cells

Published: January 30, 2026

Does Adherence to Inhaled Corticosteroids/Long-Acting β2-Agonists Matter in Patients With Severe Asthma Receiving Biologic Therapies?

Does Adherence to Inhaled Corticosteroids/Long-Acting β2-Agonists Matter in Patients With Severe Asthma Receiving Biologic Therapies?

Journal: The journal of allergy and clinical immunology. In practice

Published: July 14, 2025

TGFβ1 generates a pro-fibrotic proteome in human lung parenchyma that is sensitive to pharmacological intervention.

TGFβ1 generates a pro-fibrotic proteome in human lung parenchyma that is sensitive to pharmacological intervention.

Journal: European journal of pharmacology

Published: November 11, 2024

Assessment of an Oral Corticosteroid Withdrawal Pathway for Severe Asthma Patients Receiving Biologic Therapies.

Assessment of an Oral Corticosteroid Withdrawal Pathway for Severe Asthma Patients Receiving Biologic Therapies.

Journal: The journal of allergy and clinical immunology. In practice

Published: November 09, 2024

Urinary thromboxane and isoprostane levels are elevated in symptom-high T2-biomarker-low severe asthma.

Urinary thromboxane and isoprostane levels are elevated in symptom-high T2-biomarker-low severe asthma.

Journal: ERJ open research

Published: October 21, 2024

The role of TRP channels in lung fibrosis: Mechanisms and therapeutic potential.

The role of TRP channels in lung fibrosis: Mechanisms and therapeutic potential.

Journal: The international journal of biochemistry & cell biology

Published: September 26, 2024

Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA Study.

Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA Study.

Journal: American journal of respiratory and critical care medicine

Published: April 18, 2024

Airway tryptase levels inform the lack of clinical efficacy of the tryptase inhibitor MTPS9579A in asthma.

Airway tryptase levels inform the lack of clinical efficacy of the tryptase inhibitor MTPS9579A in asthma.

Journal: Allergy

Published: March 01, 2024

Showing 1-12 of 120

Last Updated: 09/26/2026